Plasma markers of hypercoagulability in patients with serious infections and risk of septic shock

Clinical and Applied Thrombosis/Hemostasis

Volumn 8, Issue 3, 2002, Pages 225-230

  Psuja, Piotr ^a   Zozulifńska, Maria ^a   Turowiecka, Zofia ^a   Cieślikowski, Waldemar ^a   Vinazzer, Helmut ^b   Zawilska, Krystyna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Laboratory of Haemostasis   (Austria)

Author keywords

Bacterial septicemia; Factor XIIa; Thrombin antithrombin complexes

Indexed keywords

BLOOD CLOTTING FACTOR 12A; D DIMER; FIBRINOGEN; PROTHROMBIN; PROTHROMBIN ACTIVATING FACTOR; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FIBRINOGEN METABOLISM; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RISK ASSESSMENT; SEPTIC SHOCK; SEPTICEMIA; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

EID: 0036658526     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960200800305     Document Type: Article

References (26)

1. Gando S, Kameue T, Nanzaki S, et al. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996;75:224.
2. ten Cate JW, van der Poll T, Levi M, et al. Cytokines: Triggers of clinical thrombotic disease. Thromb Haemost 1997;78:415.
3. ten Cate H, Timmerman JJ, Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999;82:713.
4. Waage A, Brandtzaeg P, Halstensen A. The complex patterns of cytokines in serum from patients with meningococcal septic shock: Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989;169:333.
5. Kalter ES, Daha MR, Verhoef J, et al. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985;151:1019.
6. Wuillemin WA, Fijnvandraat K, Derkx BHF, et al. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1996;74:1436.
7. Müller-Berghaus G, ten Cate H, Levi M. Disseminated intravascular coagulation: Clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost 1999;82:706.
8. Levi M, de Jonge E, van der Poll T, et al. Disseminated intravascular coagulation. Thromb Haemost 1999;82:695.
9. Bick RL. Disseminated intravascular coagulation: Pathophysiological mechanisms and manifestations. Sem Thromb Hemostas 1998;24:3.
10. Downey C, Kazmi R, Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998;80:65.
11. Gando S, Nanzaki S, Sasaki S, et al. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998;79:1111.
12. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101:1481.
13. Swain W. Fibrinogen assay. Clin Chem 1967;13:1026.
14. Wada H, Wakita Y, Nakase T, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;51:255.
15. Bone R. Sepsis and multiple organ failure: Consensus and controversy. In: Lamy M, Thijs LG (eds). Mediators of Sepsis. Springer-Verlag, New York, 1992:3.
16. Maruyama I: Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82:718.
17. Zeerleder S, Caliezi C, Redondo M, et al. Activation of plasma cascade systems in sepsis: Role of C1 inhibitors. Schweiz Med Wochenschr 1999;129:1410.
18. Mesters RM, Mannucci PM, Coppola R, et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88:881.
19. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127.
20. Colman R. Biologic activities of the contact factors in vivo. Thromb Haemost 1999;82:1568.
21. Pixley RA, De La Cadena RA, Page JD, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993;91:61.
22. Saetre T, Lindgaard AK, Lyberg T. Systemic activation of coagulation and fibrinolysis in a porcine model of serogroup A streptococcal shock. Blood Coagul Fibrinol 2000;11:433.
23. Raaphorst J, Johan Groeneveld AB, Bossink AW, et al. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001;86:543.
24. Jansen PM, Pixley RA, Brouwer M, et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996;87:2337.
25. Nuijens JH, Huijbregts CC, Eerenberg Belmer AJ, et al. Quantification of plasma factor XIIa-C1(-)-inhibitor and kallikrein-C1(-)-inhibitor complexes in sepsis. Blood 1988; 72:1841.
26. De La Cadena RA, Laskin KJ, Pixley RA, et al. Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation. Am J Physiol 1991;260:G213.